Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century

Shestakova M.V.

doi:https://doi.org/10.17116/terarkh201688684-88

Shestakova M.V.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century

Authors:

Shestakova M.V.

More about the authors

Journal: Therapeutic Archive. 2016;88(6): 84‑88

DOI: 10.17116/terarkh201688684-88

Read: 3642 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shestakova MV. Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century. Therapeutic Archive. 2016;88(6):84‑88. (In Russ.)
https://doi.org/10.17116/terarkh201688684-88

Использование инфографики авторами научных работ

Close metadata

Abstract:

The review gives data on the prognostic value of genetic markers when analyzing the risk of chronic kidney disease in diabetes mellitus, those on new possibilities of early diagnosis of diabetic nephropathy using urinary biomarkers (nephrinuria, podocinuria) and proteomic urinalysis at the stage of normoalbuminuria. The interpretation of the index microalbuminuria in type 2 diabetes is critically analyzed. The nephroprotective properties of novel classes of glucose-lowering drugs, such as incretins and gliflozins, are considered.

Keywords:

diabetes mellitus

chronic kidney disease

diabetic nephropathy

urinary biomarkers

urine proteomics

genetic prediction

nephroprotection

Authors:

Shestakova M.V.

Institut diabeta Éndokrinologicheskogo nauchnogo tsentra, Moskva

Close metadata

References:

International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015.
Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-272.
Bikbov B, Tomilina N. Renal replacement therapy for ESRD patients in Russian Federation, 1998—2011 Report of Russian RRT Registry. Part 1. Nefrologiay i Dialis. 2014;16(1):11-127. (In Russ.)
Shestakova M. Diabetic nephropathy: is it fatal or preventable complication? Rossiiskii meditsinskii zhurnal. 2001, 9(24):1095-1097. (In Russ.)
Shilov E, Mukhin N, Fomin V, Kutyrina I, Kuznetsova A. Diabetic nephropathy and chronic kidney failure — is it fatal event? Vrach. 2006;11:19-22. (In Russ.)
Viberti G, Karalliedde J. Commentary: The birth of microalbuminuria: a milestone in the history of medicine. Int J Epidemiol. 2014;43(1):18-20.
Tuttle KR, Bakris GL, Bilous RW et al. Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care. 2014;37:2864-2883.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3:S1-S150.
Zürbig P, Jerums G, Hovind P et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes. 2012;61(12):3304-3313.
Currie G, McKay G, Delles C. Biomarkers in diabetic nephropathy: Present and future. World J Diabetes. 2014;5(6):763-776.
Shchukina A, Bobkova I, Shestakova M, Vikulova O, Zuraeva Z, Mikhaleva O. Urinary excretion of markers for podocyte injury in patients with diabetes mellitus. Terapevticheskii arkhiv. 2015;10:62-66. (In Russ.)
Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38(6):954-962.
Klein J, Bascands J-L, Mischak H, Schanstra JP. The role of urinary peptidomics in kidney disease research. Kidney International (2016) in press; http://dx.doi.org/10.1016/
Brennan E, McEvoy C, Sadlier D, Godson C, Martin F. The Genetics of Diabetic Nephropathy. Genes. 2013;4:596-619.
Zheleznyakova A, Lebedeva N, Vikulova O, Nosikov V, Shamkhalova M, Shestakova M. Risk of chronic kidney disease in type 2 diabetes determined by polymorphisms in NOS3, APOB, KCNJ11, TCF7L2 genes as compound effect of risk genotypes combination. Sakharnyi diabet. 2014;17(3):23-30. (In Russ.)
Górriz JL, Nieto J, Navarro-González JF, Molina P et al. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med. 2015;4:1866-1889.